“Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial”. Journal of Carcinogenesis, vol. 15, no. 1, Dec. 2016, https://doi.org/10.64149/.